Glaucoma Risk Factors: Who Is Most at Risk?

Blog

Glaucoma Risk Factors: Who Is Most at Risk?

August 9, 2026

The main risk factors for glaucoma are older age, high eye pressure, a family history of glaucoma, Black or Hispanic/Latino ancestry, a thin cornea and high myopia (strong nearsightedness). [3,4,9] Eye pressure is the only one that treatment can change, and lowering it is proven to reduce the chance of glaucoma starting or getting worse. [7,8,12] When glaucoma is found and treated, most people keep useful vision for life.

The main glaucoma risk factors

  1. Older age. Glaucoma becomes more common with each decade of life.
  2. High eye pressure. The most important risk factor that treatment can change.
  3. A parent, brother, sister or child with glaucoma. Close relatives have higher risk and often need earlier eye exams.
  4. Black or Hispanic/Latino ancestry. Open-angle glaucoma is more common, starts earlier and causes more blindness in Black Americans, and risk is also higher in older Hispanic/Latino adults.
  5. A thin cornea. It can make eye pressure read lower than it is, and it predicted glaucoma in people with high eye pressure. [7]
  6. High myopia. Strong nearsightedness is linked with open-angle glaucoma and makes the optic nerve harder to assess.
  7. Narrow drainage angles. They raise the risk of angle-closure glaucoma, which can come on suddenly.
  8. Steroid use. Steroid eye drops, injections, pills, inhalers and nasal sprays can raise eye pressure in some people.
  9. Pseudoexfoliation, eye injury or inflammation. These can cause secondary glaucoma.

Diabetes, blood pressure, migraine and sleep apnea have been linked with glaucoma in some studies, but the evidence is mixed. [4,5]

What is the biggest risk factor for glaucoma?

High eye pressure is the biggest risk factor that can be treated: in the Ocular Hypertension Treatment Study, lowering it delayed or prevented glaucoma in people with high pressure. [8] Among the factors you cannot change, older age, family history and ancestry carry the most weight.

For the condition as a whole, including the types, symptoms, who is at risk, how it is diagnosed, today’s treatments and the trials testing nerve protection, read our glaucoma guide.

Intraocular pressure: important but contextual

IOP reflects the balance between aqueous humor production and outflow. Higher pressure increases mechanical stress and strain at the optic-nerve head and is the only routinely modifiable factor proven to reduce glaucoma risk and progression across major trials.

The distribution of pressure in a population does not create a sharp disease threshold. A measurement above 21 mmHg is not automatically glaucoma, and a value below 21 is not automatically safe. Target pressure is individualized to the nerve, stage, baseline, cornea and rate of change.

Pressure varies through the day and with measurement technique, body position, breath holding, eyelid squeezing, medication timing and corneal properties. A single normal visit may miss peaks; a single high reading may reflect artifact or temporary change. Repeat measurements or home tonometry can be useful in selected cases under clinician direction.

Peak, fluctuation, and cumulative exposure

Research has examined whether fluctuation independently predicts damage, but interpretation is difficult because more measurements reveal more variation and average pressure remains closely related. Clinically, recurrent peaks or inadequate control matter when they correspond to progression or a high-risk mechanism such as pseudoexfoliation.

The nerve experiences pressure over time, not only at appointments. Adherence, drop technique and access affect cumulative exposure. The goal is not to chase every small fluctuation but to maintain a safe range supported by structural and field stability.

Read more: Normal eye pressure by age.

Ocular hypertension: conversion risk rather than existing glaucoma

Ocular hypertension is elevated IOP without detectable glaucomatous optic-nerve or field damage. The Ocular Hypertension Treatment Study showed that pressure-lowering treatment reduced conversion risk, but not every participant required immediate treatment.

Risk models may include age, IOP, central corneal thickness, vertical cup-to-disc ratio and visual-field pattern standard deviation. They were built from particular cohorts and should support, not replace, clinical judgment. Modern OCT, life expectancy and patient preference add context.

Observation must include repeatable testing and a follow-up interval. “No glaucoma yet” does not mean “no risk,” while treatment should not be framed as proof that irreversible damage already exists.

Read more: Ocular hypertension (high eye pressure).

Age

Glaucoma prevalence rises with age. Retinal ganglion cells, lamina cribrosa, trabecular outflow and vascular regulation change over time, while exposure to pressure and comorbid disease accumulates.

Age also affects the consequence of risk. A young person with juvenile open-angle glaucoma has many years for damage to progress and may need a lower lifetime target. An older adult with slowly changing early disease may have a different balance of benefit, side effects and surgical burden.

Age is not a reason to deny treatment or assume loss is normal. It is one variable in projected lifetime visual risk.

Family history and genetics

First-degree relatives of people with glaucoma face higher risk because families share genetic variants, eye anatomy and sometimes access or environmental factors. The most useful history names the subtype, age at diagnosis, surgery and severity rather than simply “pressure problems.”

Primary open-angle glaucoma is usually complex and polygenic. Common variants influence IOP, optic-disc structure and ganglion-cell vulnerability. Rare variants such as MYOC can cause Mendelian juvenile or adult-onset disease in some families; OPTN and TBK1 are associated with selected normal-tension phenotypes.

Commercial polygenic scores are developing but do not replace examination. Performance can differ across ancestry groups because discovery datasets are uneven. A high score cannot diagnose damage, and a low score cannot rule it out.

Clinical genetic counseling may be appropriate for very early onset, strong multigenerational disease, developmental anomalies or a phenotype suggesting a rare gene. Relatives should not share drops or copy a treatment schedule.

Our guide to whether glaucoma is hereditary covers how much each relative’s glaucoma raises your risk and when relatives should be checked.

Population differences, race, and ancestry

In U.S. data, Black or African American populations experience higher prevalence, earlier onset and greater blindness burden from primary open-angle glaucoma. Hispanic/Latino populations, particularly at older ages, also carry substantial risk. Angle-closure prevalence is higher in many Asian populations, though enormous diversity exists within every category.

These disparities reflect some combination of ancestry-linked anatomy and genetics, social determinants, access, diagnostic delay, treatment burden, insurance and structural inequity. Race is not a precise genetic measurement. It should trigger better outreach and timely comprehensive care, not biological stereotyping.

Anyone can develop glaucoma. A White or young patient with a suspicious nerve should not be dismissed; a Black patient should not be assumed to have disease without evidence. Risk-based care must remain individualized.

Central corneal thickness and biomechanics

Goldmann applanation tonometry is influenced by corneal properties. Thinner corneas can yield lower measured pressure than thicker corneas under some conditions. In the OHTS, thinner central corneal thickness was also associated with greater conversion risk.

This does not justify adding a fixed number of millimeters of mercury from an online chart. Thickness, elasticity and geometry interact, and a numerical correction does not create a validated true pressure. Clinicians interpret pachymetry alongside the nerve and field.

Corneal refractive surgery changes thickness and biomechanics, often lowering measured applanation pressure. Prior LASIK or PRK history should be recorded. It does not protect against glaucoma and can complicate monitoring.

Myopia and hyperopia

Myopia, especially higher degrees, is associated with open-angle glaucoma and complicates diagnosis. Axial elongation changes the disc, peripapillary tissue and OCT profiles. Myopic macular or retinal disease can also cause field defects that resemble glaucoma.

Risk does not mean every thin OCT sector is glaucoma. Clinicians examine raw scans, disc photos, macular ganglion cells and change over time. Atypical central or neurologic patterns deserve broader evaluation.

Hyperopic, shorter eyes more often have crowded anterior segments and narrow angles, increasing angle-closure risk. Lens growth with age can further crowd the angle. Gonioscopy determines anatomy; eyeglass prescription alone is not enough.

Read more: High myopia and glaucoma.

Narrow angles and angle-closure risk

Angle-closure susceptibility relates to anterior chamber depth, lens position and thickness, iris configuration, age, sex, family history and ancestry-linked anatomy. Dilation or certain medications can precipitate closure in a susceptible eye, but most people taking those drugs do not have occludable angles.

A narrow angle is an anatomical finding, not automatically glaucoma. Clinicians distinguish suspect anatomy, adhesions, pressure elevation and established nerve damage. Laser peripheral iridotomy helps relieve pupillary-block mechanisms but does not eliminate every angle-closure pathway.

Patients should not avoid all antihistamines, antidepressants or dilation from internet lists. Ask an eye clinician whether the angle is actually narrow and which medications matter. Severe pain, red eye, blur, halos and nausea remain an emergency.

Read more: Angle-closure glaucoma.

Pseudoexfoliation and pigment dispersion

Pseudoexfoliation produces fibrillar material in the anterior segment and is a strong risk for higher, more variable pressure and faster glaucoma in some eyes. It may be asymmetric and can complicate cataract surgery through zonular weakness.

Pigment dispersion releases iris pigment into the drainage system, often in younger myopic people. Not everyone with pigment dispersion develops glaucoma. Gonioscopy, transillumination findings, pressure and nerve status determine risk.

These phenotypes show why a generic family or lifestyle checklist cannot replace slit-lamp and angle examination.

Steroid exposure

Corticosteroids can raise IOP by altering trabecular outflow. Risk varies with potency, route, duration and susceptibility. Eye drops and periocular or intraocular steroids generally pose greater direct risk, but inhaled, systemic and skin preparations near the eyes can matter.

People with glaucoma, ocular hypertension, family history, diabetes, high myopia or prior steroid response may deserve closer monitoring. Do not stop a steroid suddenly; uncontrolled asthma, autoimmune disease, transplantation or uveitis can be dangerous. Prescriber and eye clinician coordinate the lowest effective regimen and pressure care.

Pressure rise is usually silent, so symptom-based monitoring is inadequate.

Read more: Steroid-induced glaucoma.

Sleep apnea and nighttime physiology

Obstructive sleep apnea causes intermittent hypoxia and cardiovascular stress and has been associated with glaucoma in observational research. Study definitions, confounding and effect sizes vary. Glaucoma is not diagnosed from snoring, and normal-tension disease does not prove apnea.

Loud snoring, witnessed pauses, morning headache and daytime sleepiness deserve medical sleep evaluation for established health reasons. Continuous positive airway pressure should not be stopped because of eye-pressure speculation. Clinicians can monitor the nerve while sleep medicine treats apnea.

Sleeping face-down, tight masks or prolonged pressure on one eye can transiently affect IOP, but the long-term clinical effect is uncertain. Choose a safe sleep plan, especially after surgery, according to the treating teams.

Read more: Sleep apnea and glaucoma.

Less common or uncertain risk factors

  • Diabetes and blood pressure: linked with glaucoma in some studies, but the findings are inconsistent. Keep both well controlled for your general health, and do not change blood-pressure treatment on your own because of glaucoma.
  • Migraine and cold hands (Raynaud phenomenon): reported more often in some normal-tension glaucoma studies, but they do not reliably predict progression.
  • Other medicines: certain anticholinergic, adrenergic and sulfonamide-based drugs can trigger angle closure in people with narrow angles. [10]
  • Diet, caffeine, smoking and alcohol: no food or supplement has been proven to prevent glaucoma. [5]
  • Exercise and body position: regular exercise can lower eye pressure a little for a while; long head-down positions can raise it.
  • Air pollution and other exposures: studied, but the evidence is too early to act on. [11]
  • Sex and hormones: results vary between studies.

Risk of developing disease versus risk of progression

Before diagnosis, age, IOP, cornea, family history, optic-disc anatomy and population risk help decide surveillance or preventive treatment. After glaucoma is established, clinicians focus on:

  • current stage and central-field involvement;
  • documented structural and field rate of change;
  • achieved IOP relative to target;
  • pressure peaks and adherence;
  • disc hemorrhage;
  • bilateral disease and fellow-eye status;
  • life expectancy and functional demands; and
  • treatment tolerance and access.

A 2025 Cochrane review found moderate-certainty evidence that bilateral disease predicted field progression, and lower-certainty evidence for disc hemorrhage and treatment effects; many other proposed predictors were inconsistent or drawn from high-bias studies. This uncertainty argues for serial measurement rather than confident prophecy.

Fast progression can occur even when a demographic checklist looks mild. Stable structure and fields over adequate follow-up can justify a different plan from one based on a risk factor alone.

Building a personal screening and monitoring plan

Ask which glaucoma type is being considered, whether the angle is open, what the nerve and OCT show and whether a field defect is repeatable. Bring family history, steroid routes, trauma and prior pressure records.

Higher-risk adults need comprehensive dilated care, not only an air puff. The NEI highlights African American adults age 40 and older, adults over 60—especially Hispanic/Latino adults—and people with family history. Eye clinicians may recommend one- to two-year or more frequent examinations based on findings.

Once disease or ocular hypertension is present, the interval is individualized. A normal pressure at one visit does not cancel OCT or fields. A suspicious scan in a highly myopic eye may require repeat imaging rather than immediate lifelong labeling.

Frequently asked questions

Is high eye pressure the cause of every glaucoma case?

No. It is the main modifiable risk, but susceptibility differs and normal-tension glaucoma occurs. Diagnosis requires optic-nerve and field evidence.

If pressure is high, do I have glaucoma?

Not necessarily. Ocular hypertension lacks detectable damage. Conversion risk determines whether monitoring or treatment is appropriate.

Does a thin cornea mean glaucoma?

No. It affects IOP interpretation and may increase conversion risk in ocular hypertension. It is one part of assessment, not a diagnosis.

Can family members wait until age 60?

Not automatically. Earlier examination may be appropriate based on the relative’s subtype, age at onset and the family member’s own risk. Ask an eye clinician.

Can blood-pressure medicine worsen glaucoma?

The relationship between nocturnal pressure and progression is complex. Do not change cardiovascular treatment independently. Coordinate concerns with prescribing and glaucoma clinicians.

Will exercise prevent glaucoma?

No. Regular activity supports health and may temporarily lower IOP, but it cannot replace screening or treatment.

The bottom line

Glaucoma risk extends beyond one pressure number. Age, family history, population risk, corneal and optic-nerve anatomy, refractive shape, angle configuration and secondary exposures influence who develops disease. Once glaucoma exists, stage and measured rate of change become central.

Pressure lowering remains the proven modifiable foundation. Systemic and lifestyle factors deserve responsible health care without exaggerated promises.

Risk should be revisited when steroid exposure, eye surgery, family information or systemic health changes. A previously reasonable screening interval may need adjustment even when the patient notices nothing.

More on glaucoma

References

  1. National Eye Institute. Glaucoma. Updated 2025.
  2. National Eye Institute. Statement on Detection of Glaucoma and Adult Vision Screening. Updated 2025.
  3. Shan S, Wu J, Cao J, et al. Global incidence and risk factors for glaucoma: systematic review and meta-analysis. Journal of Global Health. 2024;14:04252.
  4. Shen RY, Zhang Y, Chen LJ, et al. Ocular and systemic risk factors and biomarkers for primary glaucoma: umbrella review. Investigative Ophthalmology & Visual Science. 2025;66:35.
  5. Rovelt J, Freiberg J, Azuara-Blanco A, Virgili G, Kolko M. Nongenetic risk factors for primary open-angle glaucoma: overview of systematic reviews. Ophthalmology Glaucoma. 2025;8:188–198.
  6. Piyasena MPP, et al. Prognostic factors associated with progression of open-angle glaucoma in adults. Cochrane Database of Systematic Reviews. 2025.
  7. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study. Archives of Ophthalmology. 2002;120:714–720.
  8. Kass MA, Heuer DK, Higginbotham EJ, et al. OHTS: topical hypotensive medication delays or prevents POAG. Archives of Ophthalmology. 2002.
  9. American Academy of Ophthalmology EyeWiki. Primary Open-Angle Glaucoma. Updated 2026.
  10. American Academy of Ophthalmology EyeWiki. Systemic Medications and Glaucoma. Updated 2026.
  11. Almarzouki N. Impact of environmental factors on glaucoma progression: systematic review. Clinical Ophthalmology. 2024;18:2705–2720.
  12. Naik V, Ohri S, Fernandez E, Mwanza JC, Fleischman D. Changes in glaucoma progression velocity after IOP-lowering therapy. PLOS ONE. 2025;20:e0324806.

Medical Disclaimer: This article provides general education and is not medical advice, diagnosis or treatment. Glaucoma risk, screening interval, target pressure and treatment require comprehensive examination by licensed eye-care professionals. Do not stop steroids, blood-pressure medicine, sleep-apnea therapy or glaucoma treatment without the relevant clinician. Severe eye pain, redness, sudden blur, halos with nausea or a sudden field change requires urgent evaluation. NRT must never delay or replace glaucoma care.

More From the Blog